Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

  • G. Andrisani Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
  • E. Gremese Rheumatology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
  • L. Guidi Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
  • A. Papa Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
  • M. Marzo Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
  • C. Felice Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
  • D. Pugliese Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
  • A. Armuzzi | alearmuzzi@yahoo.com Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.

Abstract

Inflammatory bowel disease (IBD) is commonly associated with peripheral inflammatory arthritis, and it has been estimated that as many as 12% of IBD patients report these manifestations. However, rheumatoid arthritis (RA) is rarely associated with ulcerative colitis (UC). Among all the biological agents available, nine have been currently approved for the treatment of RA. Conversely, only Infliximab and recently Adalimumab have been approved for UC. In particular, the efficacy of Adalimumab in UC has been demonstrated by both recent randomized controlled trials and real-life studies. Moreover, Adalimumab is a well-established treatment for RA. Herein, we describe a patient with RA and UC treated successfully with ADA.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biographies

G. Andrisani, Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome
Internal Medicine and Gastroenterology Unit
E. Gremese, Rheumatology Unit, Complesso Integrato Columbus, Catholic University, Rome
Rheumatology Unit
Published
2013-05-27
Info
Issue
Section
Case Reports
Keywords:
Ulcerative colitis, Rheumatoid arthritis, Adalimumab.
Statistics
  • Abstract views: 2591

  • PDF: 587
How to Cite
Andrisani, G., Gremese, E., Guidi, L., Papa, A., Marzo, M., Felice, C., Pugliese, D., & Armuzzi, A. (2013). Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis. Reumatismo, 65(2), 75-78. https://doi.org/10.4081/reumatismo.2013.75